PLEUROPARENCHYMAL FIBROELASTOSIS

PLEUROPARENCHYMAL FIBROELASTOSIS was reported 104 times

PLEUROPARENCHYMAL FIBROELASTOSIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Glycolipid Disialoganglioside-directed Antibody [EPC] 3 0.0028
1 Actinomycin [EPC] 6 0.0027
2 Lymphocyte Growth Factor [EPC] 3 0.0024
3 Topoisomerase Inhibitor [EPC] 28 0.0004
4 Alkylating Drug [EPC] 52 0.0002
5 Purine Antimetabolite [EPC] 11 0.0001
6 Lipopeptide Antibacterial [EPC] 1 0.0001
7 Nucleoside Metabolic Inhibitor [EPC] 23 0.0001
8 Pyridone [EPC] 2 0.0000
9 Antimetabolite Immunosuppressant [EPC] 1 0.0000
10 Janus Kinase Inhibitor [EPC] 7 0.0000
11 Folate Analog Metabolic Inhibitor [EPC] 17 0.0000
12 Alkaloid [EPC] 1 0.0000
13 Corticosteroid [EPC] 46 0.0000
14 Retinoid [EPC] 8 0.0000
15 Platinum-based Drug [EPC] 7 0.0000
16 Estrogen Receptor Antagonist [EPC] 1 0.0000
17 Anti-IgE [EPC] 2 0.0000
18 Aminoglycoside Antibacterial [EPC] 1 0.0000
19 Programmed Death Receptor-1 Blocking Antibody [EPC] 2 0.0000
20 Aminosalicylate [EPC] 2 0.0000
21 Macrolide Antimicrobial [EPC] 1 0.0000
22 CD20-directed Cytolytic Antibody [EPC] 6 0.0000
23 Kinase Inhibitor [EPC] 8 0.0000
24 Tetracycline-class Drug [EPC] 1 0.0000
25 Aromatase Inhibitor [EPC] 1 0.0000
26 Selective T Cell Costimulation Modulator [EPC] 1 0.0000
27 Microtubule Inhibitor [EPC] 1 0.0000
28 Factor Xa Inhibitor [EPC] 1 0.0000
29 Proton Pump Inhibitor [EPC] 2 0.0000
30 Tumor Necrosis Factor Blocker [EPC] 2 0.0000
31 Interleukin-4 Receptor alpha Antagonist [EPC] 1 0.0000
32 Benzodiazepine [EPC] 1 0.0000